Childhood acute myeloid leukemia (AML) is a fast-growing blood cancer that starts in the bone marrow, and treating it means several cycles of intensive chemotherapy given in hospital over roughly six months, with a stem cell transplant for children at higher risk of relapse. Diagnosis is confirmed with a bone marrow test, and genetic results from that sample shape almost every treatment decision that follows. Below I walk through how the disease behaves, how it is found, and what treatment actually looks like for a child and family.
What Is Childhood Acute Myeloid Leukemia?
Acute myeloid leukemia is a cancer of the myeloid line of blood cells, the family that normally matures into red cells, platelets, and infection-fighting granulocytes and monocytes. In AML, immature cells called blasts multiply without maturing and crowd out normal blood production in the marrow.
Among leukemia in children, AML is much less common than acute lymphoblastic leukemia (ALL), which makes up the large majority of childhood cases. AML can appear at any age in childhood, but it is seen more often in infants and in teenagers. It is generally harder to treat than ALL and needs more intensive therapy.
Because the marrow is where blood is made, a basic grasp of how bone marrow is built and how it works helps families understand why the symptoms look the way they do. Our leukemia guide covers the other types for comparison.
Causes and Risk Factors
In most children, no cause is ever found. AML is not caused by anything a parent did or failed to do, and it is not contagious. It arises when acquired genetic changes in a blood-forming cell disrupt the normal controls on growth and maturation.
Some conditions raise the risk:
- Down syndrome, which is linked to a distinct form of myeloid leukemia in young children that often responds well to gentler treatment.
- Inherited bone marrow failure syndromes, such as Fanconi anemia.
- Inherited cancer predisposition syndromes, including Li-Fraumeni syndrome.
- Previous chemotherapy or radiation for another cancer (therapy-related AML).
Doctors test the leukemia cells for genetic changes such as FLT3, NPM1, and RUNX1 abnormalities, and for chromosome rearrangements. These do not explain why the leukemia happened, but they are central to predicting how it will respond.
Signs and Symptoms Parents Notice
Symptoms come from the marrow failing to make enough normal blood cells, and they usually develop over days to weeks. Many look like ordinary childhood illnesses at first, which is why a simple blood count is so valuable.
| Symptom | Why it happens |
|---|---|
| Tiredness, pale skin, breathlessness | Anemia (too few red cells) |
| Easy bruising, nosebleeds, pinpoint red spots (petechiae) | Thrombocytopenia (too few platelets) |
| Fevers and repeated infections | Neutropenia (too few working white cells) |
| Bone or joint pain, limping | Leukemia cells expanding inside the marrow |
| Swollen gums, skin lumps, swollen belly | Leukemia cells collecting in gums, skin, liver, or spleen |
Unusual bruising in odd places, including along the back, is one of the signs that prompts a blood test; our article on leukemia bruises on the spine in children explains what to look for.
How Childhood AML Is Diagnosed
The first clue is usually a complete blood count (CBC). It may show a high, low, or normal white count, along with anemia and low platelets. A blood film may show blasts circulating in the blood.
The diagnosis is confirmed by bone marrow aspiration and biopsy, done under sedation or general anesthesia in children. Classically, AML is diagnosed when blasts make up at least 20% of the cells in the marrow or blood, although certain defining genetic changes allow the diagnosis at a lower blast count.
The marrow sample then goes through several tests:
- Flow cytometry to confirm the cells are myeloid rather than lymphoid.
- Cytogenetics to look for chromosome changes.
- Molecular testing for gene mutations that guide risk grouping and targeted drugs.
- A lumbar puncture to check whether leukemia cells are in the spinal fluid.
Before treatment starts, children also have heart function checked with an echocardiogram, because some key chemotherapy drugs can affect the heart. These results sit alongside the wider picture of hematological disorders that the team rules in or out.
Treating Childhood Acute Myeloid Leukemia
Treatment is intensive and is best delivered at a specialist children’s cancer center, usually within a clinical trial or a standard protocol. It runs in phases.
Induction
Induction chemotherapy aims to clear visible leukemia from the marrow and achieve remission. The backbone is cytarabine combined with an anthracycline such as daunorubicin, usually given in two courses. Children stay in hospital for much of this time because blood counts fall very low.
Consolidation
Once in remission, further courses of chemotherapy (often high-dose cytarabine) mop up leukemia cells that tests cannot yet detect. Doctors track measurable residual disease (MRD), a sensitive test for leftover leukemia, to judge response.
Stem Cell Transplant
For children with high-risk genetic features, poor early response, or relapse, an allogeneic hematopoietic stem cell transplant from a matched donor may be recommended. Children with favorable-risk disease are usually spared transplant.
Targeted and Special Cases
Drugs aimed at specific targets, such as FLT3 inhibitors or the antibody-drug conjugate gemtuzumab ozogamicin, may be added for suitable children. Acute promyelocytic leukemia, a subtype, is treated differently with all-trans retinoic acid (ATRA) and arsenic trioxide, and it carries a good outlook when managed promptly.
Supportive Care
Supportive care is as important as the chemotherapy: red cell and platelet transfusions, antibiotic and antifungal prevention, rapid treatment of fever, nutrition support, and help for the whole family.
| Phase | Main goal | Typical setting |
|---|---|---|
| Induction | Achieve remission | Inpatient, several weeks per course |
| Consolidation | Prevent relapse | Mostly inpatient, repeated courses |
| Transplant (selected children) | Replace the marrow with donor cells | Specialist transplant unit |
| Follow-up | Watch for relapse and late effects | Outpatient clinic, for years |
Life After Treatment and Late Effects
Unlike ALL, childhood AML does not usually involve years of maintenance tablets once intensive treatment finishes. Children then enter follow-up, with regular blood counts to watch for relapse, which is most likely in the first couple of years.
Long-term follow-up also watches for late effects of treatment, including heart problems from anthracyclines, growth and hormone issues, fertility effects, and, after transplant, other organ effects. Survivorship clinics exist to catch these early.
Key Takeaways
- Childhood AML is a rare, aggressive marrow cancer that needs prompt specialist care.
- Symptoms reflect low blood counts: fatigue, bruising, fevers, and bone pain.
- Bone marrow testing confirms the diagnosis, and genetic results set the risk group.
- Treatment is intensive chemotherapy in phases, with transplant reserved for higher-risk children.
- Seek urgent review for a child with unexplained bruising, persistent fever, or marked pallor.
Frequently Asked Questions
Is childhood AML curable?
Yes, many children are cured with modern treatment, although AML remains harder to treat than ALL. The outlook depends heavily on the genetic subtype and on how quickly the leukemia responds to the first courses of chemotherapy. Your child’s team can explain what their specific results mean.
How long does treatment take?
Intensive treatment usually lasts around four to six months, delivered as four or five courses of chemotherapy. If a transplant is needed, recovery adds several more months. Follow-up clinic visits then continue for years.
Could we have noticed it sooner?
Early AML symptoms look like common viral illnesses, so parents and doctors often cannot tell the difference at first. The disease develops over weeks, and a blood count is what usually reveals it. Feeling guilty is common but not justified.
Do siblings need testing?
Siblings do not need testing for AML itself, because it is not usually inherited. They may be offered tissue-type (HLA) testing if a stem cell transplant is being considered, since a matched brother or sister is often the preferred donor.
